Centre Jean Perrin
- Address
- lock Available on a paid plan
Centre Jean Perrin - Comprehensive Cancer Research Center
Centre Jean Perrin is a leading comprehensive cancer research institution conducting advanced clinical trials across multiple oncology disciplines. The center demonstrates particular expertise in genitourinary cancers, with extensive research programs in bladder, prostate, and renal cell carcinomas, as well as significant contributions to gynecologic oncology, breast cancer therapeutics, and rare tumor research.
- Urologic oncology: bladder cancer (muscle-invasive and non-muscle invasive), prostate cancer (castration-resistant and hormone-sensitive), incorporating novel immunotherapies, targeted agents, and radioligand therapies
- Gynecologic malignancies: ovarian cancer, endometrial cancer, vulvar cancer, and carcinosarcomas, with focus on immunotherapy combinations and PARP inhibitors
- Breast cancer research: hormone receptor-positive and triple-negative breast cancer, evaluating CDK4/6 inhibitors, immunotherapy, and antibody-drug conjugates
- Advanced therapeutics: head and neck cancers, lung cancer, sarcomas, neuroendocrine tumors, and pediatric brain tumors including diffuse midline gliomas
The center is at the forefront of precision oncology, conducting trials involving biomarker-driven treatment selection, including ctDNA-guided therapies, PSMA-targeted imaging and therapeutics, and genetic mutation-specific interventions. Centre Jean Perrin actively participates in international multi-center phase II and III trials, evaluating novel combinations of immunotherapy with chemotherapy, radiation therapy, and targeted agents. The institution's research portfolio encompasses the full spectrum of cancer care, from neoadjuvant and adjuvant strategies to advanced metastatic disease management, positioning it as a comprehensive center for innovative cancer treatment development.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 18 therapeutic areas and 15 of 278 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 263 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Jean Perrin
lock Showing 1 of 200 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| "CUPCAKE": Early detection of triple negative breast cancer relapse: a clinical utility trial | Institut Curie | Phase II | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 278 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 30 | Unknown | 2017-03-07 | 2025-10-02 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.